BIOTRONIK just announced FDA approval of its Lumax 740 DX System that is the first in the world to provide atrial sensing without having to use two distinct leads. Running an additional cardiac lead when the long term diagnostic benefit doesn’t clearly outweigh potential side effects is a hard decision to make. The new defibrillator will allow certain patients the benefit of atrial sensing without having another wire running through the heart.
The system relies on the Linoxsmart S DX lead that features a floating atrial dipole and special algorithms that are able to differentiate between supraventricular tachycardias (SVTs), AF and atrial flutter. The system is compatible with BIOTRONIK’s wireless Home Monitoring platform that keeps physicians updated about any relevant events detected by the implant.
From the announcement:
“Until now, our only option to obtain important and useful atrial signal information from patients undergoing defibrillator implantation has been to implant a separate atrial lead. Implanting multiple leads in the heart has been shown to increase the risk of complications2, and the use of dual-chamber devices in patients without a clear indication for the additional atrial lead has received a great deal of attention in recent months. Until now, my approach for patients who do not require atrial pacing has been to implant single-chamber ICDs,” said Bradley P. Knight, M.D., Medical Director, Center for Heart Rhythm Disorders at Northwestern Memorial Hospital’s Bluhm Cardiovascular Institute.
BIOTRONIK press release: FDA Approves First Single-Lead ICD with Atrial Sensing
Product page: Lumax 740 Series…